Clinical Trial Update: The Separate and Combined Glucagonotropic Effects of Glucose-dependent Insulinotropic Polypeptide and Alanine in Subjects With and Without Type 1 Diabetes [NA]

View source ↗

Summary

A clinical trial update describing a study of the separate and combined glucagonotropic effects of glucose-dependent insulinotropic polypeptide (GIP) and alanin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• L-alanine (L-alanine)
• glucose-dependent insulinotropic polypeptide (GIP) (glucose-dependent insulinotropic polypeptide)

Snippet

Sponsor: Asger Lund, MD | Conditions: Type 1 Diabetes | NA | Status: ACTIVE_NOT_RECRUITING